The enzyme product of SRD5A2 is expressed in androgen-dependent tissues. It is responsible for converting testosterone to the more metabolically active dihydrotestosterone, which in turn transactivates a number of genes including prostate-specific antigen
(PSA). There are a number of reports of polymorphisms and somatic mutations of SRD5A2 in prostate cancer. Polymorphisms of SRD5A2 have also been implicated in increased breast cancer risk (Bharaj, 2000).
Return to SRD5A2 Contents